← All trials
NCT06324435
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 8, 2024
- Primary completion
- Feb 28, 2025
- Completion date
- Feb 28, 2025
- First posted
- Mar 22, 2024
- Last posted
- Aug 13, 2024
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yale UniversityLead sponsor
- Yale UniversityOfficial
- Office of Research on Women's Health (ORWH)Collaborator
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.